AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Median Technologies: Financial Communication Schedule for the Second Half Of 2021

July 9, 2021 GMT

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Jul 9, 2021--

Regulatory News:

Median Technologies (Paris:ALMDT) (ALMDT), announces the publication date for its 2021 half year results (audited) and its Q3, 2021 business performance (unaudited):

Publication

Date

  • 2021 H1 results
  • Q3, 2021 business performance

Oct 14, 2021*

*Distribution after the close of trading

About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics to provide insights into novel therapies and treatment strategies. Our unique solutions for medical image analysis and management in oncology trials and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world to quickly and precisely bring new treatments to patients in need. This is how we are helping to create a healthier world.

ADVERTISEMENT

Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label “Innovative company” by the BPI and is listed on the Euronext Growth market. FR0011049824– ticker: ALMDT. Median is eligible for the French SME equity savings plan scheme (PEA-PME), listed on the Enternext® PEA-PME 150 index and has been awarded the Euronext European Rising Tech label. For more information: www.mediantechnologies.com

View source version on businesswire.com:https://www.businesswire.com/news/home/20210709005227/en/

CONTACT: Median Technologies

Emmanuelle Leygues

Head of Corporate and Marketing Communications

+33 6 10 93 58 88

emmanuelle.leygues@mediantechnologies.comPress - ALIZE RP

Caroline Carmagnol

+33 6 64 18 99 59

median@alizerp.com Investors - ACTIFIN

Ghislaine Gasparetto

+33 1 56 88 11 11

ggasparetto@actifin.fr

KEYWORD: FRANCE EUROPE

INDUSTRY KEYWORD: ONCOLOGY MEDICAL DEVICES HEALTH RADIOLOGY PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: Median Technologies

Copyright Business Wire 2021.

PUB: 07/09/2021 11:45 AM/DISC: 07/09/2021 11:45 AM

http://www.businesswire.com/news/home/20210709005227/en